Absci Corporation (ABSI)
$
3.84
-0.14 (-3.65%)
Key metrics
Financial statements
Free cash flow per share
-0.6013
Market cap
576.7 Million
Price to sales ratio
139.3592
Debt to equity
0.0418
Current ratio
4.3867
Income quality
0.6744
Average inventory
0
ROE
-0.6021
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Absci Corporation, a drug and target discovery company founded in 2011 and headquartered in Vancouver, Washington, provides biologic drug candidates and production cell lines for partners in the United States using its integrated drug creation platform. This platform unifies the processes of drug discovery and cell line development, allowing for the efficient creation of biologics. The company recorded an operating income of -$108,888,000.00 reflecting its earnings from core operations. Furthermore, with a weighted average number of diluted shares outstanding at 110,239,870.00 the company illustrates potential dilution effects. Absci reported an income before tax of -$103,036,000.00 showcasing its pre-tax profitability while earning an interest income of $0.00 highlighting the effectiveness of its financial investments. The company achieved a revenue of $4,534,000.00 indicating its niche market focus and commitment to advancing drug development. In the financial landscape, Absci’s stock is affordable at $2.61 making it suitable for budget-conscious investors. The stock has a high average trading volume of 5,393,238.00 indicating strong liquidity, which can attract a diverse range of investors. With a market capitalization of $576,668,298.00 the company is classified as a small-cap player, positioning it as a dynamic entity within the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with innovative solutions. Additionally, Absci belongs to the Healthcare sector, driving innovation and growth, and emphasizing its pivotal role in shaping the future of drug discovery and development.
Is Absci Corporation (ABSI) a good investment?
Investing in Absci Corporation (ABSI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Absci Corporation (ABSI)'s stock forecast?
Analysts predict Absci Corporation stock to fluctuate between $2.01 (low) and $6.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Absci Corporation's market capitalization?
As of 2025-12-11, Absci Corporation's market cap is $576,668,298, based on 150,369,830 outstanding shares.
How does Absci Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Absci Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Absci Corporation (ABSI) stock?
To buy Absci Corporation (ABSI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABSI. Place an order (Market, Limit, etc.).
What is the best time to invest in Absci Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Absci Corporation perform in the last earnings report?
Revenue: $4,534,000 | EPS: -$0.94 | Growth: -21.67%.
Where can I find Absci Corporation's investor relations reports?
Visit https://www.absci.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Absci Corporation?
You can explore historical data from here
What is the all-time high and low for Absci Corporation stock?
All-time high: $28.28 (2021-08-09) | All-time low: $1.11 (2023-10-26).
What are the key trends affecting Absci Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript
zacks.com
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
fool.com
Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.
seekingalpha.com
Absci Corporation ( ABSI ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Sean McClain - Founder, CEO, President & Director Presentation Operator It's my pleasure to now introduce Sean McClain, CEO; and Zach Jonasson, CFO of Absci Corporation. Just a reminder, there will be a 20-minutes presentation following with 5 minutes Q&A.
seekingalpha.com
Absci Corporation ( ABSI ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Andreas Busch - Chief Innovation Officer & Member of Scientific Advisory Board Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Brendan Smith - TD Cowen, Research Division Sean Laaman - Morgan Stanley, Research Division Gil Blum - Needham & Company, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Operator Thank you for standing by. My name is Rochelle, and I will be your operator today.
zacks.com
Absci Corporation (ABSI) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.24 per share a year ago.
marketbeat.com
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn.
benzinga.com
Absci Inc. ABSI on Thursday collaborated with Oracle Corporation's ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery.
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. MidCap biotech equity research.
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senior Vice President of Drug Creation Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Alexander Xenakis - Unidentified Company Truist Securities - Unidentified Company Arseniy Shabashvili - Guggenheim Securities, LLC, Research Division Brendan Mychal Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Morgan K. Gryga - Morgan Stanley, Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Swayampakula Ramakanth - H.C.
See all news
